Loading
After CAR-T the blood counts often take much longer to recover than after ordinary chemotherapy, and in some people they dip again weeks later after appearing to have recovered. Since 2023 this has had a name, ICAHT, and an agreed grading system, which matters because it means it is measured and reported rather than described loosely.
Haematological toxicity is the commonest adverse event after CAR-T therapy and the one that lasts longest. In 2023 the European Society for Blood and Marrow Transplantation and the European Hematology Association convened an international panel of 36 CAR-T experts and published a consensus grading system and best practice recommendations, naming the entity immune effector cell-associated haematotoxicity, or ICAHT. The panel's own account of why it was needed is that a worldwide survey had shown considerable heterogeneity in practice patterns.
The grading system is built on the depth and duration of neutropenia and distinguishes early ICAHT, from day 0 to day 30, from late ICAHT, after day plus 30. That split is the clinically important observation: haematopoietic reconstitution after CAR-T does not follow the pattern of chemotherapy-associated myelosuppression. Counts can recover and then fall again, a biphasic course that is characteristic and is why a normal count at day 28 is not the end of the matter. The consensus also provides recommendations on risk factors, on pre-infusion scoring systems including the CAR-HEMATOTOX score, and on diagnostic work-up, with a section on identifying haemophagocytosis in the context of severe haematotoxicity.
Why it happens is not fully understood and the field says so. A review in 2024 concluded that the underlying pathophysiology remains poorly understood, and that translational studies from the preceding three years suggest CAR-T-induced inflammation and baseline haematopoietic function are key contributors to prolonged cytopenia. In other words: how much marrow reserve a person arrives with, worn down by prior lines of chemotherapy, and how much inflammation the CAR-T cells generate, together explain much of what follows. The CAR-HEMATOTOX score, calculated before infusion, exists to identify people at high risk in advance so that risk-based interventions can be planned.
Management, in the consensus panel's own framing, covers growth factor support, anti-infective prophylaxis, transfusions, autologous haematopoietic stem cell boost and allogeneic transplantation. Granulocyte colony-stimulating factor is the mainstay. For people refractory to it, a stem cell boost using previously cryopreserved autologous cells is available where such cells were stored, which is one reason storage decisions made before CAR-T matter later. Anti-infective prophylaxis follows the neutropenia rather than the calendar.
The clinical consequence that makes this worth a record of its own is that ICAHT drives infection, transfusion dependence, prolonged hospital stay and a share of non-relapse mortality. The grading system does not treat anything; what it does is make the problem countable, comparable between centres and reportable in trials, which is the precondition for anything else. A second paper from the same group describes an automated computational implementation of the grading criteria, benchmarked manually and computationally in two independent cohorts totalling 1,251 patients, because manual grading proved time-consuming and subject to error.
No grade is attached to this record: it describes a complication and its grading, not an intervention to recommend or warn against. The interventions it names, growth factor support and stem cell boost, rest on consensus recommendation rather than on randomised evidence in this setting, which the panel states.
CAR-T therapy injures haematopoiesis by two routes that are not the direct cytotoxicity of lymphodepletion. Systemic inflammation, driven by the expanding CAR-T cells and by cytokine release syndrome, suppresses the marrow niche and skews progenitors; and the baseline haematopoietic reserve of a heavily pretreated patient, often with clonal haematopoiesis, is low to begin with. Because inflammation waxes and wanes with CAR-T expansion, recovery is biphasic rather than monotonic.
Query for this technology: (TITLE:"Blood counts that do not come back after CAR-T: ICAHT" OR ABSTRACT:"Blood counts that do not come back after CAR-T: ICAHT" OR TITLE:"ICAHT" OR ABSTRACT:"ICAHT" OR TITLE:"immune effector cell-associated haematotoxicity" OR ABSTRACT:"immune effector cell-associated haematotoxicity" OR TITLE:"prolonged cytopenia after CAR-T" OR ABSTRACT:"prolonged cytopenia after CAR-T") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Blood counts that do not come back after CAR-T: ICAHT, not a curated reading list.
Shares Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says, After a transplant or cell therapy: what to ask for, Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, transplant, cell-therapy.
Shares B-cell aplasia and low antibodies after CAR-T and bispecifics, and immunoglobulin replacement, Rebuilding an immune system: the timeline, lineage by lineage, Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it, After a transplant or cell therapy: what to ask for and the tags rejuvenation, survivorship, transplant.
Shares Cytopenias and myelosuppression, After a transplant or cell therapy: what to ask for, Autologous stem cell transplant (high-dose therapy), Late effects and survivorship toxicity and the tags rejuvenation, survivorship, transplant.
Shares Rebuilding an immune system: the timeline, lineage by lineage, Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it, After a transplant or cell therapy: what to ask for, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, transplant.
Shares ICANS, and whether thinking recovers after CAR-T, After a transplant or cell therapy: what to ask for, Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, transplant.
Shares Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says, Clonal haematopoiesis after cancer treatment, After a transplant or cell therapy: what to ask for, Late effects and survivorship toxicity and the tags rejuvenation, survivorship, transplant.
Shares Rebuilding an immune system: the timeline, lineage by lineage, After a transplant or cell therapy: what to ask for, Autologous stem cell transplant (high-dose therapy), Late effects and survivorship toxicity and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship, cell-therapy.